Case Study: UF | DF Development Challenges – Gap in Scale-Down Technologies for Tangential Flow Filtration

The biopharmaceutical industry is currently facing a number of challenges. In recent years, companies have experienced a decline in peak sales of their newly launched products while at the same time the cost of developing a new biological drug continues to increase. The industry’s pipeline of products is becoming increasingly diverse and requires production platforms that are more adaptable and flexible than ever before. Take ultra- and diafiltration operations, for example. Increasingly, biopharmaceutical companies seek to increase the concentration of their final product, e.g., for subcutaneous injections. It is imperative that they understand the stability of their final product and how this can be influenced with different buffer solutions.